• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

顺铂及其一水合物与调节剂(二)巯乙磺酸钠和硫代硫酸盐的反应动力学

Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate.

作者信息

Leeuwenkamp O R, Neijt J P, van der Vijgh W J, Pinedo H M

机构信息

Department of Oncology, Free University Hospital, Amsterdam, The Netherlands.

出版信息

Eur J Cancer. 1991;27(10):1243-7. doi: 10.1016/0277-5379(91)90090-z.

DOI:10.1016/0277-5379(91)90090-z
PMID:1835593
Abstract

The reactive and rapidly excreted thiol mesna (2-mercaptoethane-sulphonate sodium) has the potential to reduce the dose-limiting nephrotoxicity of cisplatin by chemical neutralisation of the latter in the kidney. The reaction kinetics of cisplatin with mesna and its disulphide, dimesna, was studied at 37 degrees C in unbuffered 0.15 mol/l NaCl (pH 5.3) and in 0.15 mol/l NaCl buffered with 0.02 mol/l Hepes (pH 7.4). The reaction mixtures were analysed for intact cisplatin. In the presence of mesna or dimesna 0.5 mol/l as anticipated in urine for conditions of renal protection, the half-life (t1/2) of 0.2 mmol/l cisplatin was less than 6 min. t1/2 of 151 and 629 min were found in the presence of mesna and dimesna concentrations of 5 mmol/l and 3 mmol/l, respectively, anticipated in plasma under conditions of renal protection. Cis-diamminemonoaquamonochloroplatinum(II) 0.2 mmol/l reacted rapidly with 50 mmol thiosulphate and 0.5 mol/l (di)mesna (t1/2 less than or equal to 1 min). This platinum species also reacted rapidly with 2.6 mmol/l thiosulphate (t1/2 less than 1 min), a concentration reached in plasma for conditions under renal protection. Reaction of the monoaquated form of cisplatin proceeded slowly in the presence of dimesna or mesna concentrations (less than 5 mmol/l), as anticipated in plasma under renal protecting conditions. It is hypothesised that renal protection by the strong nucleophiles, thiosulphate, mesna and dimesna occurs rather by neutralisation of the aquated species in the lumen of the renal tubulus than by neutralisation of intact cisplatin, and that neutralisation of these species in plasma contributes significantly to the protecting effect.

摘要

反应迅速且排泄快的硫醇美司钠(2-巯基乙烷磺酸钠)有可能通过在肾脏中对顺铂进行化学中和来降低顺铂的剂量限制性肾毒性。在37℃下,于未缓冲的0.15mol/L氯化钠(pH5.3)以及用0.02mol/L Hepes缓冲的0.15mol/L氯化钠(pH7.4)中,研究了顺铂与美司钠及其二硫化物二巯基乙烷磺酸钠的反应动力学。对反应混合物中的完整顺铂进行分析。在肾脏保护条件下尿液中预期的0.5mol/L美司钠或二巯基乙烷磺酸钠存在时,0.2mmol/L顺铂的半衰期(t1/2)小于6分钟。在肾脏保护条件下血浆中预期的美司钠和二巯基乙烷磺酸钠浓度分别为5mmol/L和3mmol/L时,t1/2分别为151分钟和629分钟。0.2mmol/L顺二氨一氯一水铂(II)与50mmol硫代硫酸盐和0.5mol/L(二)美司钠迅速反应(t1/2小于或等于1分钟)。该铂物种也与2.6mmol/L硫代硫酸盐迅速反应(t1/2小于1分钟),这是肾脏保护条件下血浆中达到的浓度。在肾脏保护条件下血浆中预期的二巯基乙烷磺酸钠或美司钠浓度(小于5mmol/L)存在时,顺铂的一水合物形式的反应进行缓慢。据推测,强亲核试剂硫代硫酸盐、美司钠和二巯基乙烷磺酸钠对肾脏的保护作用,更多是通过中和肾小管管腔中的水合物种,而非完整顺铂的中和来实现的,并且这些物种在血浆中的中和对保护作用有显著贡献。

相似文献

1
Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate.顺铂及其一水合物与调节剂(二)巯乙磺酸钠和硫代硫酸盐的反应动力学
Eur J Cancer. 1991;27(10):1243-7. doi: 10.1016/0277-5379(91)90090-z.
2
Reaction kinetics of cisplatin and its monoaquated species with the (potential) renal protecting agents (di)mesna and thiosulfate. Estimation of the effect of protecting agents on the plasma and peritoneal AUCs of CDDP.
Cancer Chemother Pharmacol. 1990;27(2):111-4. doi: 10.1007/BF00689093.
3
The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG.BNP7787及其代谢产物美司钠与细胞抑制剂顺铂的化学反应性:与亲核试剂硫代硫酸盐、二乙氨基二硫代甲酸钠、谷胱甘肽及其二硫化物谷胱甘肽二硫化物的比较。
Cancer Chemother Pharmacol. 2003 Jun;51(6):499-504. doi: 10.1007/s00280-003-0610-3. Epub 2003 Apr 25.
4
Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.
J Clin Pharmacol. 1997 Jul;37(7):618-24. doi: 10.1002/j.1552-4604.1997.tb04344.x.
5
Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.大鼠体内2-巯基乙烷磺酸钠的药代动力学与代谢
Cancer Res. 1983 Jan;43(1):333-8.
6
Ifosfamide and mesna: effects on the Na/H exchanger activity in renal epithelial cells in culture (LLC-PK1).异环磷酰胺和美司钠:对培养的肾上皮细胞(LLC-PK1)中钠/氢交换体活性的影响。
Ren Physiol Biochem. 1995 May-Jun;18(3):118-27. doi: 10.1159/000173909.
7
Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.正常受试者静脉注射与口服2-巯基乙烷磺酸钠(美司钠)的药代动力学
Br J Clin Pharmacol. 1987 May;23(5):561-8. doi: 10.1111/j.1365-2125.1987.tb03092.x.
8
Enzymatic and non-enzymatic mechanisms of dimesna metabolism.二巯基丁二酸钠代谢的酶促和非酶促机制。
Amino Acids. 2015 Mar;47(3):511-23. doi: 10.1007/s00726-014-1882-0. Epub 2014 Dec 10.
9
Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.二硫代双巯基乙烷磺酸盐(美司钠)不能预防异环磷酰胺和环磷酰胺的代谢产物对LLC-PK1细胞造成的细胞损伤。
Pediatr Nephrol. 1994 Aug;8(4):458-65. doi: 10.1007/BF00856531.
10
Reduction of dimesna to mesna by the isolated perfused rat liver.离体灌注大鼠肝脏将二巯基丁二酸钠还原为美司钠。
Cancer Res. 1998 Oct 1;58(19):4358-62.

引用本文的文献

1
Mesna (2-mercaptoethane sodium sulfonate) functions as a regulator of myeloperoxidase.美司钠(2-巯基乙烷磺酸钠)作为髓过氧化物酶的调节剂发挥作用。
Free Radic Biol Med. 2017 Sep;110:54-62. doi: 10.1016/j.freeradbiomed.2017.05.019. Epub 2017 May 25.
2
Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer.BNP7787,一种新型化学保护剂,在晚期非小细胞肺癌患者中的 I 期和药物研究。
Cancer Chemother Pharmacol. 2011 Mar;67(3):533-42. doi: 10.1007/s00280-010-1340-y. Epub 2010 May 15.
3
Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.
新型化学保护剂BNP7787与顺铂联合应用的I期及药代动力学研究以及取消水化方案的尝试
Br J Cancer. 2005 May 9;92(9):1636-43. doi: 10.1038/sj.bjc.6602553.
4
Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.化学保护剂BNP7787和美司钠在大鼠静脉推注后的药代动力学行为。
Br J Cancer. 2004 Apr 19;90(8):1654-9. doi: 10.1038/sj.bjc.6601719.
5
Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.美司钠对小儿癌症患者顺铂和卡铂药代动力学的影响。
Med Oncol. 2004;21(1):9-20. doi: 10.1385/MO:21:1:09.
6
Pharmacokinetic drug interactions with anticancer drugs.抗癌药物的药代动力学药物相互作用。
Clin Pharmacokinet. 1994 Jun;26(6):486-500. doi: 10.2165/00003088-199426060-00006.